In the first-line setting, management of metastatic nccRCC varies by histology, but often include similar therapies to metastatic ccRCC, such as anti-VEGF TKIs, ICIs, other targeted agents such as MET inhibitors, and more rarely cytotoxic chemotherapy. The gene discussed is MET; the disease is nonpapillary renal cell carcinoma.